

PRESS RELEASE

Milan, 10th June 2022

Spindox joins the University of Florence's Scarab Lab with Dynamedics

Spindox signs a partnership with the University of Florence in the renewed joint Scarab Lab, engaged in research and development projects in the pharmacological, medical and health fields.

Spindox S.p.A. (the “Company” or “Spindox”, TICKER: SPN), a leading company in the market of ICT (Information & Communication Technology) services and products for digital innovation in corporate business, officially announces the partnership with the University of Florence in the **renewed joint [Scarab Lab](#)**, which is engaged in **research and development projects in the pharmacological, medical and health fields**.

Part of this joint laboratory is also [Dynamedics](#), a recognised spin-off of the University of Florence in which Spindox has a direct stake, specialised in consultancy for the realisation of technological and software solutions in the world of healthcare and pharmacology.

The partnership with the joint Scarab Lab was born in March 2018 with Plan Soft, a new entry of the Spindox group. The intention is to join efforts and create ad hoc **technological solutions for national and international research projects related to the Lab** together with the university research activity carried out by the staff of the [Department of Neuroscience, Psychology, Pharmaceutical Area and Child Health](#) of the University of Florence.

The aim is to develop products and technologies according to the scientific and technological state of the art, which integrate the best features of the Laboratory's members: the biomedical and scientific knowledge and expertise of the university staff and Dynamedics with Spindox's IT and software development technologies.

The value of this collaboration is linked to the multidisciplinary composition of the laboratory staff (physicians, pharmacologists, computer scientists, biomedical engineers), which enables the identification of scientific and clinical, as well as technical, needs and priorities that can optimise the design, creation and management phases of the product, as well as workflows.

The Laboratory's focus is the creation of **innovative and efficient services and products for research in pharmacology, pharmacovigilance, pharmacoepidemiology and healthcare**, while improving the cost/benefit ratio as much as possible. Some of the research areas in which the Laboratory is involved include:

- IT applications for clinical pharmacological data, pharmacovigilance and pharmacoepidemiology.
- IT solutions for the pharmacological treatment of patients suffering from chronic and acute diseases.
- Information systems for the collection, storage and analysis of preclinical and clinical data, with particular reference to pharmacology and pharmacovigilance.
- Big data and machine learning for healthcare, pharmacology, pharmacoepidemiology and pharmacovigilance.
- HTA (Health Technology Assessment) and new technologies in healthcare (medical devices, electromedical devices, etc.).



Giulia Gestri, Spindox's Chairman of the Board, says: "The partnership with Scarab Lab marks another step in the path we chose for the positioning of our company in the market of technologies for the pharmaceutical and biomedical industry. The skills we bring to the Laboratory, both in the field of information technology and artificial intelligence, can contribute to the development of extremely innovative solutions in this sector. We are also pleased that, through this partnership, the relationship between Spindox and the University of Florence will be activated. Collaboration with academic institutions and the world of research, in Italy and at a European level, has always represented our way of being. Working with the prestigious University of Florence makes us very proud."

Alfredo Vannacci, Head of Scientific Research at Scarab Lab, says: "The entry of Spindox into our Joint Laboratory represents an event of extraordinary importance for both the research group and the University. The company's excellent technological expertise will be hugely beneficial to the development of the pharmacological research lines we are working on, particularly with regard to the evaluation of the efficacy and safety of drugs and vaccines in the real world. The so called 'real-world evidence' increasingly interfaces with clinical research today: as the pandemic has shown us, it is extremely important (and always will be) to have highly responsive technological tools, based on big data and artificial intelligence, to respond in real time to the challenges we face everyday. The experience of our group, which covers a wide range of disciplines from basic research to clinical medicine, from pharmacy to biomedical engineering, not forgetting our ongoing commitment to the Third Sector and perinatal health, can only benefit significantly from this new partnership, in which we have great confidence."

This partnership will allow access to multiple innovative research and development projects, both nationally and internationally, with extremely positive spin-offs in terms of knowledge sharing."

Scarab Lab

The "Technological Solutions for Clinical Pharmacology, Pharmacovigilance and Bioinformatics Laboratory" ("SCARAB LAB") was set up in April 2016, with the aim of formalising in a single structure the multiple information technology activities in pharmacology, pharmacovigilance and healthcare conducted, within the Department of Neuropharmacy, by the unit directed by Professor **Alfredo Vannacci**. In March 2018, Plan Soft joined the Lab with the aim of increasing its technical skills, which had become necessary following the increase in number and importance of the projects carried out. Scarab Lab is directed by Professor Alfredo Vannacci, who is also Head of Scientific Research at Dynamedics, and coordinated by Engineer **Roberto Bonaiuti**, respectively Scientific and Technical Head of the lab and CEO of the University spin-off Dynamedics. Other participants in the lab's activities are Dr. **Niccolò Lombardi** and Dr. **Giada Crescioli**, two pharmacists with many years of experience in the fields of pharmacovigilance and pharmacoepidemiology, and Dr. **Sandro Pinna**, an expert in pharmaco-economics.

Dynamedics

Dynamedics is a spin-off approved by the University of Florence and born within the Department of Neuropharmacy where, for more than a decade, the clinical and technical staff of the research area in pharmacology, pharmacovigilance and pharmacoepidemiology have been working on the creation of information **systems for regional, national and international research projects** related to the health data flow, with particular reference to the safety and efficacy of **drugs, parapharmaceuticals and medical devices**. Dynamedics' solutions are conceived, designed and implemented together with healthcare professionals, analysing the clinical, regulatory and application needs of the specific healthcare context from a clinical and healthcare professional perspective.

About Spindox

Spindox operates in the ICT services and products market, positioning itself as a company that designs, develops and integrates innovation. It is one of the top 50 companies in the sector in our country by turnover (source: IDC / Data Manager, 2020 data) and one of those with the highest growth rate over the last four years (CAGR 2017-2021 of



21%). The group has more than 1,000 employees (as at 31 December 2021) spread across nine Italian offices: Milan, Rome, Maranello, Turin, Florence, Cagliari, Trento, Bari and Ivrea and four foreign offices in Spain, Switzerland, the UK and the USA. Spindox's mission is to support its customers' business innovation by offering consultancy, IT and network engineering services, integrating technology, research and artificial intelligence.

Spindox S.p.A.

Head office: Via Bisceglie 76, 20152 – Milano

Referent: Paolo Costa – Chief Marketing and Communications Officer, Investor Relator

Contacts: paolo.costa@spindox.it - +39 02 910 95101

Investor Relations & Market Advisor

KT & Partners

Chiara Cardelli / Kevin Tempestini

ccardelli@ktepartners.com – tel. 02 83424008

Mob: +39 3387129015

Media Relations

Spriano Communication & Partners

Via Santa Radegonda, 16 - 20121 Milano

Matteo Russo: Mob: +39 347 9834 881 mrusso@sprianocommunication.com

Fiorella Girardo: Mob: +39 348 8577766 fgirardo@sprianocommunication.com

Euronext Growth Milan Advisor

EnVent Capital Markets Ltd

London, in Berkeley Square, 42, W1J54W,

E-mail: mdinardo@enventcapitalmarkets.uk



Spindox S.p.A.

Sede legale: Via Bisceglie 76, 20152 – Milano MI Italy